Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

We believe Genmab is in solid financial health. At the end of 2024, Genmab held DKK 9.9 billion in cash and cash equivalents. After turning profitable in 2013, the company has steadily increased its ...

Novavax (NVAX) has recently seen a decrease in stock value, dropping after announcing Q4 results that missed revenue expectations. The company ...

Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies.

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my post earnings update for NVAX stock.

Sanofi’s addition to the Series C round builds on Enveda’s continued success in bringing novel therapeutics inspired by evolution from discovery to clinical trials. Enveda has made remarkable progress ...

On his first day in office in 2021, former President Joe Biden revoked a permit for the Keystone XL pipeline. The next day, the company behind the project said it would eliminate about 1,000 jobs.

Sanofi licensed the antibody from Alopexx Pharmaceuticals, a precursor to the current biotech of the same name, in 2009 but faced challenges such as the slow enrollment (PDF) of a phase 2a trial.

Sanofi’s addition to the Series C round builds ... Enveda has made remarkable progress in building a deep pipeline of molecules with novel mechanisms of action that address pressing medical ...